Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
Ardelyx, a biopharmaceutical company (Nasdaq: ARDX), will participate in the 2024 Jefferies Global Healthcare Conference. Michael Raab, President and CEO, alongside Justin Renz, Chief Financial and Operations Officer, will engage in a fireside chat on June 5, 2024, at 10:00 A.M. Eastern Time in New York City. The event will be accessible via live webcast on the Ardelyx website, with a replay available for 30 days after the event.
- Participation in the prestigious 2024 Jefferies Global Healthcare Conference can enhance Ardelyx's visibility and credibility in the biopharmaceutical industry.
- Engagement by high-ranking officials like the CEO and CFO at such events indicates strong leadership involvement and transparency.
- The availability of a live webcast and a 30-day replay offers extensive access for investors and stakeholders, promoting transparency and engagement.
- No specific financial or clinical updates were provided in this announcement, which might be seen as a lack of new substantial progress or news.
- The stock performance might not see immediate or significant impact solely based on participation in an industry conference.
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx participate in the Jefferies Global Healthcare Conference?
Who from Ardelyx will be participating in the 2024 Jefferies Global Healthcare Conference?
How can I access the live webcast of Ardelyx's presentation at the 2024 Jefferies Global Healthcare Conference?
Will a replay of Ardelyx's presentation at the 2024 Jefferies Global Healthcare Conference be available?
What is the stock symbol for Ardelyx?
